Stock YB3 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Company Shin Nippon Biomedical Laboratories, Ltd. BOERSE MUENCHEN

Equities

YB3

JP3379950003

Biotechnology & Medical Research

Real-time BOERSE MUENCHEN
Other stock markets
 20:43:44 01/07/2024 BST 		5-day change 1st Jan Change
8.2 EUR -2.38% Intraday chart for Shin Nippon Biomedical Laboratories, Ltd. +1.82% -22.22%
05-08 Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Forecasts for the Six Months Ending September 30, 2024 and Year Ending March 31, 2025 CI
02-02 Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024 CI

Business Summary

SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. is a Japan-based company mainly engaged in the provision of clinical trials and drug development services for pharmaceutical companies. The Company has four business segments. The Preclinical segment is engaged in the verification of the effectiveness and safety of new drugs by conducting tests on experimental animals, cells and bacteria. The Clinical segment is engaged in the verification of the effectiveness and safety of test articles on human. The Translational Research segment is involved in the research and development of pharmaceutical products and related technology, as well as the conduction of preclinical and clinical trials, among others. The Others segment is engaged in information collecting business, the sale of environmental analysis equipment, and the operation of accommodation. As of March 31, 2013, the Company had 27 subsidiaries and one associated company.

Sales per Business

JPY in Million2023Weight2024Weight Delta
Contract Research Organization
97.0 %
23,924 95.4 % 25,661 97.0 % +7.26%
Medipolis
1.8 %
601 2.4 % 478 1.8 % -20.52%
Others
1.1 %
549 2.2 % 300 1.1 % -45.29%
Translational Research
0.0 %
16 0.1 % 12 0.0 % -29.19%

Sales per region

JPY in Million2023Weight2024Weight Delta
Japan
67.3 %
18,515 73.8 % 17,812 67.3 % -3.80%
United States
16.9 %
3,843 15.3 % 4,482 16.9 % +16.62%
South Korea
14.2 %
-- 3,763 14.2 % -
Other
1.5 %
2,733 10.9 % 393 1.5 % -85.61%

Managers

Managers TitleAgeSince
Ryoichi Nagata CEO
 Chief Executive Officer 65 31/08/81
Shinji Nitanda DFI
 Director of Finance/CFO 55 30/04/02
Terumasa Hirai CMP
 Compliance Officer - 31/03/84
Shunji Haruta CTO
 Chief Tech/Sci/R&D Officer - 31/03/01
Ken Takanashi COO
 Chief Operating Officer 60 30/11/02
Ichiro Nagata BRD
 Director/Board Member 38 31/03/17
Kyomi Nagatoshi IRC
 Investor Relations Contact - 31/01/02
Hiroyuki Izumi PRN
 Corporate Officer/Principal - 31/03/92
Masakazu Suda AUD
 Comptroller/Controller/Auditor 62 31/07/90
Toshihiko Makino AUD
 Comptroller/Controller/Auditor - 31/03/05

Members of the board

Members of the board TitleAgeSince
Ryoichi Nagata CEO
 Chief Executive Officer 65 31/08/81
Ichiro Nagata BRD
 Director/Board Member 38 31/03/17
Shuichi Kanazashi SAM
 Sales & Marketing 64 31/10/02
Satoshi Matsumoto PRN
 Corporate Officer/Principal 56 31/05/99
Shinji Nitanda DFI
 Director of Finance/CFO 55 30/04/02
Hideshi Tsusaki PRN
 Corporate Officer/Principal 57 31/03/96
Shinichi Fukumoto BRD
 Director/Board Member 66 31/05/15
Takashi Yamashita BRD
 Director/Board Member 68 31/05/15
Tsuyoshi Hanada BRD
 Director/Board Member - 25/06/20
Keiko Toya BRD
 Director/Board Member 60 31/05/21

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 41,632,400 19,291,331 ( 46.34 %) 469 ( 0.001127 %) 46.34 %

Shareholders

NameEquities%Valuation
Nagata Family
40.33 %
16,788,600 40.33 % 145 M €
Takahisa Nagata
4.876 %
2,030,000 4.876 % 18 M €
Asset Management One Co., Ltd.
3.930 %
1,636,100 3.930 % 14 M €
Medipolis Medical Research Institute
3.541 %
1,474,000 3.541 % 13 M €
Ikue Nagata
2.460 %
1,024,000 2.460 % 9 M €
Rie Umehara
2.460 %
1,024,000 2.460 % 9 M €
KYUSHU FINANCIAL GROUP,INC.
2.402 %
1,000,000 2.402 % 9 M €
Goldman Sachs Asset Management Co., Ltd. (Japan)
0.9654 %
401,900 0.9654 % 3 M €
Goldman Sachs Asset Management BV
0.1506 %
62,697 0.1506 % 541 809 €
SBI Asset Management Co., Ltd.
0.1321 %
55,000 0.1321 % 475 294 €

Holdings

NameEquities%Valuation
WAVE LIFE SCIENCES LTD.
53.83%
 2,100,000 53.83% 12,978,000 $
TMS CO., LTD.
3.56%
 1,433,320 3.56% 1,915,417 $
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.
0.00%
 400 0.00% 3,457 $

Company contact information

Shin Nippon Biomedical Laboratories, Ltd.

St. Luke's Tower, 28/F 8-1 Akashi-cho

104-0044, Tokyo

+81 9 9294 3389

http://www.snbl.co.jp
address Shin Nippon Biomedical Laboratories, Ltd.(YB3)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sales per Business

Sales per region

Ratings for Shin Nippon Biomedical Laboratories, Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1,395 JPY
Average target price
2,800 JPY
Spread / Average Target
+100.72%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MODERNA, INC. Stock Moderna, Inc.
+16.59% 45.51B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-9.89% 38.52B
LONZA GROUP AG Stock Lonza Group AG
+38.08% 38.13B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+27.12% 30.74B
CELLTRION, INC. Stock Celltrion, Inc.
-8.64% 26.03B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.81% 25.92B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+45.08% 14.13B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+32.85% 12.73B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-7.19% 11.29B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 2395 Stock
  4. YB3 Stock
  5. Company Shin Nippon Biomedical Laboratories, Ltd.